^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ICT01

i
Other names: ICT01, IV ICT01, humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody, ICT 01, ICT-01, IV ICT-01, IV ICT 01
Associations
Trials
Company:
ImCheck Therap
Drug class:
γδ TCR modulator, CD277 agonist
Associations
Trials
4ms
EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov)
P1/2, N=150, Recruiting, ImCheck Therapeutics | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Jun 2025
Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Metastases
|
Keytruda (pembrolizumab) • ICT01
4ms
EVICTION-2: Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=100, Recruiting, ImCheck Therapeutics | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • Proleukin (aldesleukin) • ICT01
1year
Evaluation of ICT01, a γ9δ2 T Cell-Activating Monoclonal Antibody, Combined with Venetoclax and Azacitidine in 1L AML (EVICTION Study) (ASH 2023)
ICT01, a first-in-class anti-BTN3A mAb activating γ9δ2 T cells, completed Phase 1 testing in relapsed/refractory (r/r) solid tumors as monotherapy and in combination with pembrolizumab, and as monotherapy in r/r AML and lymphoma (EVICTION-NCT04243499). Encouraging results obtained in the EVICTION Phase 1 trial and preclinical demonstration of the benefit of using ICT01 plus VEN/AZA allowed the initiation of a Phase 2a expansion cohort to evaluate the clinical benefit of this combination in 1L AML patients.
PD(L)-1 Biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL17A (Interleukin 17A) • IL4 (Interleukin 4)
|
Keytruda (pembrolizumab) • Venclexta (venetoclax) • azacitidine • ICT01
over1year
EVICTION-2 Clinical Trial: Combining ImmunoCytokines and ICT1 to Expand Endogenous Gamma9Delta2 T Cells (IO-SUMMIT EUROPE 2023)
However, the pharmacodynamic effects of ICT01 are dependent on the number of circulating gamma9d2 T cells, which is low in most advanced cancer patients. Preclinical studies showed that ICT01 plus IL-2 induces selective expansion of gamma9d2 T cells with minimal Treg expansion supporting an ongoing Phase I/IIa (EVICTION-2) in patients with advanced-stage solid tumors.
Clinical
|
IL2 (Interleukin 2)
|
ICT01
2years
EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov)
P1/2, N=150, Recruiting, ImCheck Therapeutics | Trial completion date: Dec 2022 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Mar 2024
Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Metastases
|
CD69 (CD69 Molecule)
|
Keytruda (pembrolizumab) • ICT01
over2years
TARGETING BTN2A1 BY A UNIQUE ACTIVATING MAB IMPROVES ANTI-TUMOR FUNCTIONS OF VΓ9VΔ2 T CELLS (EHA 2022)
BTN3A targeting agonist antibody ICT01 is being developed in a multicentric Phase 1 and 2 study called EVICTION by Imcheck Therapeutics...ALL samples were also tested for their expansion capacities after 14 days of PBMC culture in presence of Zoledronate...These results indicate that the sensitization of leukemic cells can be induced by activation BTN3A as reported previously as well as with BTN2A1 mAbs. These findings could be of great interest for the design of innovative Vγ9Vδ2 T cells-based immunotherapy strategies for treating ALL that could be extended to other cancer types.
IO biomarker
|
BTN2A1 (Butyrophilin Subfamily 2 Member A1) • BTN3A1 (Butyrophilin Subfamily 3 Member A1)
|
zoledronic acid • ICT01
almost3years
EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov)
P1/2, N=150, Recruiting, ImCheck Therapeutics | Phase classification: P1 --> P1/2
Phase classification • Combination therapy • Checkpoint inhibition
|
CD69 (CD69 Molecule)
|
Keytruda (pembrolizumab) • ICT01
3years
Targeting BTN2A1 By a Unique Activating Mab Improves Vγ9Vδ2 T Cell Cytotoxicity Against Primary Acute Lymphoblastic Blasts (ASH 2021)
BTN3A molecules are targeted at clinical level, with the ICT01 agonist monoclonal antibody (mAb), that is currently tested in a multicentric phase ½ study (EVICTION study)...These data bring novel understanding on the biology of BTN2A1 on leukemic cells and our ability to enhance both binding and function. These findings could be of great interest for the design of innovative Vγ9Vδ2 T cells-based immunotherapy strategies for treating ALL that could be extended to other cancer types.
IO biomarker
|
BTN2A1 (Butyrophilin Subfamily 2 Member A1) • BTN3A1 (Butyrophilin Subfamily 3 Member A1)
|
ICT01